Research programme: antibacterial protein-based therapeutics - Phico Therapeutics

Drug Profile

Research programme: antibacterial protein-based therapeutics - Phico Therapeutics

Alternative Names: PT2.0; PT3; PT3.33; PT3.X; PT4.0; PTS3.2; SASP programme; SASPject™ PT3.1; SASPject™ PT3.X; SASPject™PT2.0; SASPject™PT4.0; SASPject™PTS3.2

Latest Information Update: 25 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Phico Therapeutics
  • Class Peptides
  • Mechanism of Action Bacterial DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 09 Mar 2015 Preclinical development is underway in United Kingdom
  • 12 Sep 2012 Pharmacodynamics data from preclinical studies in Bacterial infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012) ,
  • 19 Apr 2008 Antimicrobial data from a preclinical trial in Bacterial infections presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top